再迎布局窗口？港股通创新药ETF（520880）四连阳后下挫4%！重磅催化即将来袭！

Group 1 - The Hong Kong stock market for innovative drugs opened high but fell, with Zai Lab leading the decline by over 13% and other companies like Innovent Biologics and Ascentage Pharma dropping over 5% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a significant drop of over 4%, with a trading volume of nearly 350 million yuan [1] - The ETF had previously seen four consecutive days of gains, reaching a new closing high [1] Group 2 - The World Lung Cancer Conference (WCLC) will take place from September 6 to 9 in Barcelona, Spain, where Chinese pharmaceutical companies will showcase innovative drug results [3] - Companies such as CanSino Biologics, BeiGene, and Baillie Gifford will present their latest research during the conference [3] - The upcoming conferences and the peak season for licensing agreements with multinational pharmaceutical companies (MNCs) are expected to create a favorable environment for innovative drugs in the coming quarter [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, with a year-to-date increase of 118.95%, leading among various innovative drug indices [3][4] - The ETF is set to revise its index compilation rules to exclude companies primarily engaged in CXO services, focusing solely on innovative drug research and development [5] - This revision is expected to enhance the ETF's performance during the upward cycle of the innovative drug industry [5]